Swiss pharma giant Novartis (NOVN: VX) has signed an agreement with LFB Group company Cell for Cure for the manufacture of CAR-T therapies.
The deal will see these cancer medicines, which are personalized for each patient according to their own blood cells, manufactured at the major LFB Group site in Les Ulis in the suburbs of Paris, France.
Production could begin in 2019 after the transfer of manufacturing technologies from Novartis to Cell for Cure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze